ArticleActa diabetologica2026
Astaxanthin administration attenuates capillary regression in soleus muscles of rats with streptozotocin-induced diabetes.
Article in Acta diabetologica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
aimsDiabetes induces skeletal muscle atrophy and capillary regression, especially in oxidative muscles, such as the soleus (SOL). Capillary regression impairs oxygen and substrates delivery, and contributes to metabolic dysfunction and vascular complications. Although protective effects of antioxidants have been demonstrated in disuse models, their role in diabetes-induced capillary regression remains unclear. We examined whether dietary astaxanthin supplementation attenuates capillary regression in the SOL muscles of rats with streptozotocin-induced diabetes.
methodsTwenty-four male Wistar rats (6 weeks old) were randomly divided into three groups: control (CON), streptozotocin-induced diabetes (STZ), and STZ with astaxanthin supplementation (STZ + AST). Diabetes was induced by a single tail vein injection of streptozotocin (STZ; 50 mg/kg). Astaxanthin (100 mg/kg/day) was orally administered to the STZ + AST group for 6 weeks. The SOL muscles were analyzed for the capillary-to-fiber (C/F) ratio, oxidative stress (dihydroethidium [DHE] staining), and expression of angiogenesis- and AGEs-related proteins by western blotting.
resultsRats in the STZ group exhibited decreased muscle C/F ratio, increased DHE fluorescence, and elevated FOXO1 and TSP-1. Astaxanthin supplementation significantly improved the C/F ratio and reduced excessively generated ROS and anti-angiogenic protein expression. In addition, the VEGF-A/TSP-1 ratio improved in the STZ + AST group rats. Although the RAGE levels remained elevated, a downward trend was observed following astaxanthin treatment. DISCUSSION: Astaxanthin supplementation attenuated diabetes-induced capillary regression in the SOL muscles by suppressing oxidative stress and modulating angiogenic signaling. These findings suggest a therapeutic potential for protecting the skeletal muscle microvasculature under diabetic conditions.
Indexed as
Identifiers
41774172What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.